Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | FNTA | P49354 | 7/20 | 0.48 |
| ▸ | FNTB | P49356 | 7/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GRB2 | P62993 | 1/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 3/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30052866 | 0.91 | GRB2 (0.53) | XIAPFNTAFNTBLMNAGRB2 | |
| SCHEMBL30052397 | 0.91 | XIAP (0.48) | XIAPFNTAFNTBLMNAGRB2 | |
| SCHEMBL30216522 | 0.91 | XIAP (0.46) | XIAPFNTAFNTBLMNAGRB2 | |
| SCHEMBL29575751 | 0.90 | NTSR2 (0.46) | FNTAFNTBGRB2KMT2A | |
| SCHEMBL30051457 | 0.89 | DPP4 (0.46) | XIAPFNTAFNTBLMNAGRB2 | |
| SCHEMBL30052876 | 0.88 | XIAP (0.53) | XIAPFNTAFNTBLMNAGRB2 | |
| SCHEMBL30397733 | 0.87 | XIAP (0.55) | XIAPGRB2SLC6A2ACEREN | |
| SCHEMBL29350341 | 0.86 | ACE (0.54) | XIAPGRB2SLC6A2ACEREN | |
| SCHEMBL29482768 | 0.86 | ACE (0.54) | XIAPGRB2SLC6A2ACEREN | |
| SCHEMBL9002927 | 0.85 | LMNA (0.48) | XIAPFNTAFNTBLMNAPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| CN-113278049-B | Selenium-rich flavor peptide separated from selenium-rich seaweed, preparation method and application | 国民康健(北京)自然科学研究有限公司 | 2022-04-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | XIAP 4043/4885FNTA 734/4885FNTB 479/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | XIAP 2121/4885FNTA 776/4885FNTB 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.